– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –

– Enables Greater Impact Across ADHD Patient Communities –

– AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue –

– Expected Patent Protection into 2037 –

– Transaction Expected to be Immediately Accretive to Adjusted EBITDA –

– Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan –

– Conference Call Scheduled for Today at 9:00 a.m. ET –

STOUGHTON, Mass. and CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and Corium Therapeutics Holdings, LLC (Corium Therapeutics), today announced a definitive agreement pursuant to which Collegium will acquire AZSTARYS for $650 million in cash with the potential for additional milestone payments up to $135 million depending on future commercial and regulatory milestones.

Corium Therapeutics is a privately held company that, through its subsidiaries, markets and distributes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. It is the first and only ADHD treatment with both immediate release and long-acting medicines in one capsule. The acquisition of AZSTARYS is expected to significantly strengthen Collegium's position in ADHD, further diversifying and bolstering its revenue base.